$5.55
TScan Therapeutics is a biotechnology business based in the US. TScan Therapeutics shares (TCRX) are listed on the NASDAQ and all prices are listed in US Dollars. TScan Therapeutics employs 175 staff and has a trailing 12-month revenue of around $12.2 million.
Our top picks for where to buy Tscan Therapeutics stock
How to buy TScan Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TCRX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy TScan Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
TScan Therapeutics stock price (NASDAQ: TCRX)
Use our graph to track the performance of TCRX stocks over time.TScan Therapeutics shares at a glance
Latest market close | $5.55 |
---|---|
52-week range | $2.35 - $9.69 |
50-day moving average | $6.29 |
200-day moving average | $6.67 |
Wall St. target price | $12.57 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.65 |
Is it a good time to buy TScan Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
TScan Therapeutics price performance over time
Historical closes compared with the close of $5.55 from 2024-09-06
1 week (2024-08-30) | -1.42% |
---|---|
1 month (2024-08-07) | -1.94% |
3 months (2024-06-07) | -33.77% |
6 months (2024-03-07) | -22.27% |
1 year (2023-09-07) | 112.64% |
---|---|
2 years (2022-09-07) | 44.53% |
3 years (2021-09-07) | 8.99 |
5 years (2019-09-03) | N/A |
TScan Therapeutics financials
Revenue TTM | $12.2 million |
---|---|
Gross profit TTM | $-46,284,000 |
Return on assets TTM | -20.16% |
Return on equity TTM | -46.84% |
Profit margin | 0% |
Book value | $4.82 |
Market Capitalization | $298.2 million |
TTM: trailing 12 months
TScan Therapeutics share dividends
We're not expecting TScan Therapeutics to pay a dividend over the next 12 months.
TScan Therapeutics share price volatility
Over the last 12 months, TScan Therapeutics's shares have ranged in value from as little as $2.35 up to $9.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TScan Therapeutics's is 0.823. This would suggest that TScan Therapeutics's shares are less volatile than average (for this exchange).
To put TScan Therapeutics's beta into context you can compare it against those of similar companies.
- Pluristem (PSTI.US): 1.9127
- Neximmune (NEXI.US): 1.85
- ZIOPHARM Oncology (ZIOP.US): 1.6868
TScan Therapeutics overview
TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc.
Frequently asked questions
What percentage of TScan Therapeutics is owned by insiders or institutions?Currently 0.883% of TScan Therapeutics shares are held by insiders and 99.45% by institutions. How many people work for TScan Therapeutics?
Latest data suggests 175 work at TScan Therapeutics. When does the fiscal year end for TScan Therapeutics?
TScan Therapeutics's fiscal year ends in December. Where is TScan Therapeutics based?
TScan Therapeutics's address is: 830 Winter Street, Waltham, MA, United States, 02451 What is TScan Therapeutics's ISIN number?
TScan Therapeutics's international securities identification number is: US89854M1018
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
5 top graphene stocks to invest in today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question